


Q² pub M

--15. The use of compounds of the formula (I)




in which

Ar is an aromatic or heteroaromatic ring system having a single ring;


X^1 is NR^3R^4 , OR^3 , SR^3 , COOR^3 , CONR^3R^4 or COR^5 ,

where


R^3 is H or a group of the formula II, IIIa, IIIb or IIIc:




(II)



(IIIa)



(IIIb)



(IIIc)

where

Acct


X^2 is NH, NR⁴, O or S,
 X^3 is NH, NR⁴, O, S, CO, COO, CONH OR CONR⁴,
Y is C(R⁸)₂,
R⁴ is H or an alkyl, alkenyl or alkynyl radical,
R⁷ is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical or -
SO₂-R⁹,
R⁸ is in each case independently H, halogen or an alkyl, alkenyl,
alkynyl, aryl or/and heteroaryl radical,
R⁹ is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical and
n is an integer from 0 to 2,
R⁴ is as defined above,
R⁵ is H, an alkyl, alkenyl, alkynyl, carboxyalkyl, carboxyalkenyl,
carboxyalkynyl, carboxyaryl or carboxyheteroaryl radical;
R² is halogen, C(R⁶)₃, C₂(R⁶)₅, OC(R⁶)₃ or OC²(R⁶)₅,
where
R⁶ is in each case independently H or halogen, in particular F; and
m is an integer from 0 to 4;
or salts of said compound for preparing an agent for inhibition of the urokinase
plasminogen activator.

16. The use as claimed in claim 15, in which Ar is a benzene ring.
17. The use as claimed in claim 16, in which the substituents -CH₂X¹ and -
NHC(NH)NH₂ are arranged in para position.

A2 cont.

18. The use as claimed in claim 15, in which R⁷ and R⁹ are selected from the group comprising aryl, in particular phenyl radicals and tertiary alkyl radicals and cycloalkyl radicals, in particular bicycloalkyl radicals such as adamantyl.

19. The use of compounds of the formula (IV)



in which

X¹ is in each case independently NR³R⁴, OR³, SR³, COOR³, CONR³R⁴ or COR⁵, with the proviso that the two arylguanidine groups are linked to one another via the substituents CH₂X¹,

where

R³ is in each case independently H or any organic radical,

R⁴ is in each case independently H or an alkyl, alkenyl or alkynyl radical;

Ar is in each case independently an aromatic or heteroaromatic ring system,

R² is in each case independently halogen, C(R⁶)₃, C₂(R⁶)₅, OC(R⁶)₃ or OC₂(R⁶)₅,

where


R⁶ is in each case independently H or halogen, in particular F; and

m is an integer from 0 to 4;

or salts of said compounds for preparing an agent for inhibition of the urokinase plasminogen activator.

Q2 cont

20. The use as claimed in claim 15 for controlling disorders which are associated with a pathological overexpression of urokinase or/and urokinase receptor.
21. The use as claimed in claim 20 for controlling tumors.
22. The use as claimed in claim 20 for controlling the formation of metastases.
- Part B2*
23. The use as claimed in claim 15 for preparing orally, topically, rectally or parenterally administrable medicaments.
24. The use as claimed in claim 15 in the form of tablets, coated tablets, capsules, pellets, suppositories, solutions or transdermal systems such as plasters.
25. A method for inhibiting urokinase in living creatures, in particular in humans, by administering an effective quantity of at least one compound as claimed in claim 15.
26. A compound of the formula (I)



in which Ar, X^1 , R^2 and m are as defined in claim 15.